Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "IMI"

4532 News Found

Granules India opens advanced Centres of Excellence in Hyderabad
R&D | December 01, 2025

Granules India opens advanced Centres of Excellence in Hyderabad

Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides


a2z wins FDA nod for groundbreaking abdomen-pelvis CT AI Triage system
News | November 30, 2025

a2z wins FDA nod for groundbreaking abdomen-pelvis CT AI Triage system

Abdomen-pelvis CT is the nation’s highest-volume CT category


Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI
Drug Approval | November 29, 2025

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States


Mangalam Drugs receives Rs. 15 crore repeat export order
News | November 29, 2025

Mangalam Drugs receives Rs. 15 crore repeat export order

The receipt of this order further strengthens the company's position in the global pharmaceutical market


Innoxel Lifesciences completes EU GMP inspection by Belgium's FAMHP
Drug Approval | November 29, 2025

Innoxel Lifesciences completes EU GMP inspection by Belgium's FAMHP

The audit was completed with zero critical and zero major observations


Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility
News | November 29, 2025

Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility

This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility


Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
News | November 28, 2025

Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight